The recent identification of two of the genes involved in familial breast and ovarian cancer has generated widespread media interest. This has resulted in unrealistic expectations from both the public and the medical profession as to the ease and likely availability of genetic testing to predict cancer susceptibility. In reality, these recent findings will have direct relevance to only a small number of individuals with a family history of ovarian cancer.
A strategy for the management of those presenting with a family history of ovarian cancer will be presented. This strategy allows stratification into high risk, moderate risk and low risk groups. Those considered at high risk are offered BRCA1 testing. The important clinical messages to convey to those wishing to embark on BRCA1 testing will be outlined, emphasising many of the commonly held misconceptions.
Those at moderate risk are offered regular screening. A study of regular screening with annual ultrasound and CA125 estimation for those at significantly increased risk of familial ovarian cancer will be described.
The implications, possible drawbacks and potential problems inherent in this management policy will be considered.
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TREATMENT OF EARLY OVARIAN CANCER S. Pecorelli, European Institute of Oncology, Milan, Italy Ovarian cancer is the fifth leading cause of death in women in the USA and the most common cause of death in women with gynaecological malignancies in most westem countries. Of the ovarian cancers, 85-90% are epithelial and more that two-third are stage III and IV. Comprehensive surgical staging enables the selection of appropriate additional therapy, provides information to determine prognosis and offers the patient the best chance for cure. As no randomised trials on the primary surgical management have been performed, only an indirect indication of its impact can be given. In the past, several randomised trials have been performed to test the value of adjuvant therapies following surgery in early stage disease. The majority of these suffered from a number of short comings, i.e. omission of a therapy-free arm in the high-risk early disease stages, inclusion of borderline tumours, incomplete surgical staging or inclusion of patients with stage II or III with minimal residual disease. More recent trials indicated that when comprehensive surgical staging is performed, patients with well differentiated or moderately differentiated cancer confined to the ovaries (stages IA and IB) do not need any additional therapy. Non-randomised studies using comprehensive surgery in stage I-IIA grade I patients confirmed this and also suggested that patients who wished to retain their reproductive function could even qualify for conservative surgery. In all other early stage disease cases with less favourable features, the situation is less clear since randomised trials have not included a no-treatment control arm. In patients with grade 3 stage I tumours or with cancer outside the ovaries but limited to the pelvis (stage II) or with clear cell carcinoma, the recommendation in the US is to use adjuvant therapy. At present, it is generally believed in the US that chemotherapy is preferable to radiotherapy or i.p. 32P. In Europe, some studies evaluating the role of adjuvant therapy in early ovarian cancer patients did not show an overall survival benefit for those treated in the adjuvant setting versus those treated on relapse. From retrospective reviews of stage The United Kingdom Coordinating Committee on Cancer Research (UKCCCR) provides a forum for the coordination of research activities between the main cancer research funding bodies in the UK (ie the CRC, ICRF and MRC). A major task is the facilitation of national and international cancer clinical trials and other multicentre studies in the UK. Amongst current UKCCCR trials are the QUASAR trial of chemotherapy in colorectal cancer, the 'Age' and 'Frequency' trials in breast cancer screening, and the 'Aim High' trial of alpha interferon in melanoma. Each trial steering group reports to one of the UKCCCR site-specific subcommittees which in turn report to the Trials Committee (Chairman, Prof Nick Thatcher) When a proposed clinical trial comes to the attention of the UKCCCR it is initially prioritised by the Trials Committee. If it appears that joint funding by two or more of the funding bodies is appropriate, then a 'lead' funding body is identified. This body will then carry out peer review of the proposal on behalf of itself and the other involved funding bodies. In parallel with this, the UKCCCR Secretariat will organise detailed protocol review. At the end of the day, however, each individual funding body makes its own decision regarding the priority for a given proposal and the funding to be awarded.
The MRC has recently introduced a system whereby trial 'outlines' are judged at a very early stage. For those proposals which pass this stage, the NHS R&D are then informed about the trial in order that appropriate service costs can be earmarked should the trial be funded. The precise way whereby UKCCCR trials can slot into this system is currently under discussion. All organisms have evolved an intricate network of complementary DNA repair systems, to cope with DNA damage induced by endogenous or exogenous genotoxic agents These systems are crucial to ensure genetic stability and prevent mutagenesis and carcinogenesis. Defects in DNA repair result in hypersensitivity to genotoxic agents and carcinogenesis.
The nucleotide excision repair (NER) pathway for elimination of UV-induced lesions is understood in great detail and is associated with three clinically and genetically heterogeneous human syndromes characterized by marked sun sensitivity: xeroderma pigmentosum (XP), Cockayne syndrome (CS) and trichothiodystrophy (TTD). XP patients show an over 100Ox increased risk of skin cancer, in contrast to CS and TTD. The latter disorders display severe developmental abnormalities and neurodysfunction. In addition TTD is characterized by sulphurdeficient brittle hair and nails, due to a reduced synthesis of cysteine-rich matrix proteins. At least 10 genes are involved, virtually all of which have been cloned. Some of the encoded proteins appeared also implicated in other cellular processes, explaining puzzling clinical features associated with defects in these genes. The proteins defective in TTD and in 2 of the complementation groups with combined XP/CS reside in the TFIIH complex, involved in basal transcription and in NER. Many of the CS and TTD features may be due to a crippled TFIIH transcription function, affecting the expression of a specific set of genes. To understand the complex genotype-phenotype relationship we have generated mouse models by gene targeting in embryonal stem cells. The present knowledge of the mechanism and biological impact of this and other damage repair pathways will be summarized. The induction of the p53 response to ionising radiation has been studied during murine development and in the adult animal. The response has been assessed by precise quantitative assay of p53 protein levels in tissues and by immunohistochemistry. Newly developed transgenic mice in which a lacZ transgene is driven by a p53 response element have also been used to directly assess the transcriptional activity of the induced protein. There is striking developmental control of the p53 response so that in early development all tissues accumulate high levels of p53 following radiation and indeed p53 is present at elevated levels in some unirradiated tissues. Later in development clear heterogeneity of the p53 response becomes apparent, both in terms of the responses of individual tissues and of cell populations within those tissues. The study of lacZ transgene expression and the occurrence of apoptosis in different tissues that accumulate p53 protein point to a further level of control regulating the nature and degree of the downstream response to elevated levels of p53 in cells. These findings have important implications for the susceptibility of different tissue types to carcinogenic and other insults. The early expression of the p53 response is consistent with novel models of p53 function that suggest it may have evolved principally as a defence against teratogenic insult that permits plasticity of development. Research Council, Harwell, Oxfordshire OX1 1 ORD, UK.
The biological consequences of exposure to genotoxic agents include gene mutation, chromosome aberrations, cellular transformation and cell death. These effects are attributed to irreversible changes fixed during DNA replication or during the processing of the DNA damage by enzymatic repair processes. Accordingly, it has been generally accepted that most of these changes take place during the cell cycles immediately following exposure. Genomic instability may arise as a consequence of mutational changes in genes, the products of which are involved in recognising, responding to or repairing DNA damage. However, evidence is rapidly accumulating that apparently normal cells that have survived genotoxic insults may produce descendants in which a high frequency of de novo chromosome aberrations and gene mutations arise or in which there is an enhanced death rate. These delayed effects are manifestations of an induced genomic instability, a phenotype induced at frequencies considerably greater than conventional mutation frequencies. At present little is understood of the processes involved in the initiation of inducible instabilities and in the maintenance and transmission of the phenotype over many generations of cell replication. Furthermore, there is no reason to suppose that all the various end points are necessarily attributable to a common mechanism. To date, genomic instability induced by ionizing radiation has been more extensively studied than instability induced by chemical agents and it is becoming evident that the expression of inducible instability has a strong dependence on the type of radiation exposure, the cell type irradiated and the genetic "predisposition" of the irradiated cell. Loss of suppressor gene function occurs frequently in human cancers. Concentrating on the p53, p16 and p21, we have sought to identify small molecules that can regulate the activity of these cell cycle regulatory proteins and to create synthetic tumour suppressor proteins. A detailed biochemical analysis of the p53 tumour suppressor protein has established that it is produced in a latent inactive form that is activated for DNA binding by modification of a negative regulatory domain at the C terminus of the protein. Direct microinjection of anti-C terminal activating antibodies has been shown to activate the transcriptional function of wild type and mutant p53 in vivo establishing the potential therapeutic capability of such activators. We have designed synthetic suppressor proteins by localising the kinase inhibitory domain of the p16 and p21
proteins. Synthetic peptides containing these domains linked to transport peptide sequences have been prepared. The complete 36 amino acid synthetic mini proteins are taken up from the tissue culture medium and is able to block cell cycle progression. These approaches not only provide novel insight into protein-protein interactions involved in suppressor gene function, but are also leading directly to the design and discovery of novel anti cancer treatments. The twin revolutions in molecular biology and nonlinear mathematics generate a wide range of exciting opportunities for the application of the mathematics to oncology. In particular, theoretical models can act as a link between data and hypotheses at the cellular and molecular level, and macroscopic observations. The mathematics of complex systems provides a toolkit which enables the implications of nonlinear interactions within a single cell, or in biochemical interactions between cells, to be studied. I will discuss briefly a number of examples of modelling studies, focussing in particular on a theoretical model of matrix degradation during tumour invasion. Protease production and altered cell motility are key components of the invasive phenotype; I will describe a model enabling their interplay to be studied in detail. The model uncovers a number of new biological results, in particular suggesting a novel mechanism for the parabolic dependence of invasion on protease production. I will conclude by summarising the current applications and future potential for nonlinear mathematical modelling of cancer biology.
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Mathematics on a Sunday afternoon in Scotlandl M Baum ChM FRCS Department of Surgery, University College London, 67-73 Riding House Street, London WI P 7LD
The management of cancer is based on conceptual models we have of the disease. From time to time these models must approximate to reality as judged by the therapeutic successes. However these therapeutic successes have been most marked in the management of childhood cancer the leukemia's and lymphomas. Successes in the management of solid tumours have been much more modest. Therefore we should acknowledge that our conceptual frameworks which determine our treatments are seriously flawed. Models of cancer can either be biological or mathematical. The biological models are more familiar and often appear as schematic diagrams in text books of tumour biology. However mathematical modelling is less familiar to the clinical oncologist.
The simplest examples of mathematical modelling are those originally described by Skipper, upon which the rationale of cyclical chemotherapy is based. In other words we conceptualise that metastases grow according to logrhythmic or Gompertzian functions and that each cycle of chemotherapy is responsible for log cell kill. It will be the purpose of this presentation to illustrate how flawed this approach must be and how the description of breast cancer survival as hazard rates with time illustrates the bankruptcy of the conventional paradigm. To replace this model will present as an example a new paradigm that describes breast cancer and micrometastases as complex organisms in a state of dynamic equilibrium existing close to a chaotic boundary. will advocate new mathematical approaches to explore these concepts and also the inevitable therapeutic sequelae of such a conceptual revolution. Biology systems are extremely complex and cannot be satisfactorily evaluated with linear mathematics. This is even more so for analysing disorder of complex systems or disease. Time series analysis using chaos mathematics may be a more appropriate method of prediction of incidence of infection of malignancy and response of a population to treatment and the application of non-linear mathematics to individual patients with a complex disease such as cancer, may help determine which patients will develop metastatic disease and/or a local recurrence.
Skipper, H.E. (1967) Criteria associated with destruction of
The morphogenesis of tissues in embryo, wound healing and the growth patterns of neoplasia can already be modelled mathematically and complex medical images from both pathology and radiology, can be analysed by determining fractal dimensions and patterns.
In a chaotic system the unpredictable behaviour arises because of minute variations in the starting conditions which are amplified in a non-linear manner, such that it is never possible to exactly repeat the sequence. Within such chaos, trends can appear which are known as attractors and these attractors can create order and measures of complexity out of the chaos. For example, correlations between different prognostic indicators for tumour development will emerge from chaotic data by the lure of the attractor.
Even starting with a few simple variables in order to model tumour spread the progression of a mutant cell within a primary is remarkably unpredictable and similar to the patterns obtained when trying to model and forecast weather systems. The mathematics involved in modeling secondary spread are likely to be distinct from those of the primary in that the patterns of growth are different being gomperzian in the primary, and gradual growth probably reflecting the establishment of neo-angiogenesis in the secondary, which undergoes a late growth spurt once angiogenesis has been achieved. Nevertheless the chaos inherent in the state of malignancy forms patterns or follows an attractor and that modeling of the relevant variables may result in greater understanding of how a tumour type will behave hence a better understanding of what should constitute appropriate preventative treatment. Neural networks and non-linear modeling have been used in a prediction and prognosis of breast cancer showing that survival curves can be produced for individual patients with a greater predictive power than conventional techniques such as Cox's proportional hazard model. It is remarkable that the application of these techniques to complex pathology such as cancer are only just now being attempted. It is important to be aware that as well as the complexity and chaos that can result from a very simple reiteration, the converse is also often also true in that simplicity in nature is often generated from chaos and complexity in that this probably represents the action of extemal constraints. Indeed, systems are interactive and co-involve in a manner that changes both leading to a growth of complexity from simple beginnings, yet leading to a complexity that is unpredictable in detail but whose general course is comprehensible and predictable and it is this that would be a tremendous advance to the management of cancer, if these principles could be applied in the clinical situation. New drug development has changed considerably from accidental findings to rational design. Whereas in particular the limited predictability of preclinical models on the clinical antitumor activity had initially led to scepticism on each others research potentials, in the past decade new drug development has more and more evolved into a close collaboration between basic and clinical researchers.
Increasingly, the flow of obtained information is going back and forth, stimulating further research at both sides. This is also induced by the short periods of patency-protection, necessitating the shortest possible development time. There are now some nice examples of how this system should function appropriately. Less than 30% of NSCLC patients present with tumour where surgery or radical radiotherapy with curative intent is the treatment of choice. More effective chemotherapy offers an avenue of progress but is hampered by traditional views that chemotherapy is unacceptably toxic, and is without survival advantage. Until recently few active agents, ifosfamide, cisplatin, mitomycin C, vindesine (>15% OR) had been identified. Recently a number a new active agents, gemcitabine, taxanes, topoisomerase I inhibitors , vinorelbine have in more rigorous evaluation been shown to be effective [1] . Gemcitabine a new pyrimidine antimetabolite is of particular interest in having a very favourable toxicity profile. Combinations of these new and older agents are now being examined in phase II and very recently in phase m trials. Advanced stage. mB / IV disease: Chemotherapy using older agents ie. non platinum containing alkylating therapy in general showed no benefit in randomised trials over best supportive care which included palliative radiotherapy. However, more recent trials have revealed significant survival benefit in a majority of studies [1] . The most recent meta-analysis has again indicated survival benefit when chemotherapy was added to best supportive care in the palliative setting [2] . These data reflect -a subpopulation of patients who significantly benefit from the addition of chemotherapy even when objective response rates are only 30% or less.
con'td..... Persistent or recurrent thoracic disease occurs in the majority of lung cancer patients treated with radiotherapy alone.
A major obstacle to increasing radiation dose,is the inability of conventional technology to overcome the limitations imposed by normal tissue tolerance. This may be partially overcome by the use of 3-DCRT.
The pre-clinical evaluation of this modality demonstrated that it had the technical potential to enhance the therapeutic ratio. Subsequent trials of dose escalation have demonstrated feasibility and reasonable toxicity and promising outcome. The utilisation of 3-DCRT has represented a major cultural shift in the methods by which radiotherapy is delivered for lung cancer. The ICRU 50 recommendations for target volume definitions will be addressed. These guidelines can be used to devise methods of target volume definition for 3-DCRT. The ability of 3-DCRT systems to devise dose volume histograms allows calculation of normal tissue complication probabilities. These calculated probabilities can be used as an objective method for comparison of candidate treatment plans. Furthermore they provide exciting opportunities for predicting complication risks for individual patients.
The the potential for refinement of these models by incorporation of functional studies will also be addressed. Finally, potential clinical strategies for ongoing research will be outlined. Endocrine communication is founded on the concept that a target organ may be influenced by secreted chemical messengers from another source. This is classically evident in premenopausal women in whom ovarian secretion of oestrogen regulates breast development; the converse principle underpins the benefits of ovarian ablation in the treatment of premenopausal breast cancer. However, in addition to such distant controls, there is evidence to suggest that, particularly in postmenopausal women, local hormonal influences are equally important. The primary basis for this is the observation that tumoural levels and profiles of steroid hormones, especially oestrogens, differ from those in the circulation. This phenomenon must involve some active process -either selective concentration and sequestration against a concentration gradient or local hormone synthesis. There is evidence for both but the relative contribution to the hormoneal environment differs between individual tumours. For oestrogen synthesis the potential is present in both mammary adipose tissue and the breast tumour itself (although there is controversy as to whether stromal or epithelial cells are the primary site of production) and these may therefore supply cancer cells with the hormones they require for growth. Equally cytokines and other factors elaborated by tumour cells may induce local oestrogen synthesis completing a trophic loop. The particular molecules and second messenger systems involved are incompletely defined, but the advent of potent, specific inhibitors and their use in experimental protocols of primary systemic treatment mean that powerful tools are now available by which this knowledge may be derived and the clinical relevance of such intra-tumoural endocrinology confirned.
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SCOTTISH BREAST CANCER AUDIT. J A DEWAR, Dept. Radiotherapy & Orncology, Niniewells Hospital, Dunidee (oni behalf of the Scottish Catncer Therapy Network).
The populatiorn studies were all niew cases of inlvasive breast canicer registered in Scotlarnd int 1987 anid 1993, comprisitng 2148 arid 2549 cases respectively (89% and 97% of eligible cases). Comparitng the two years, the proportioni matnaged surgically itncreased from 75% to 81% aind of these, there was ani inicrease itn the % treated cornservatively (40 to 52%). Only 55%.of these patienits had post-operative radiotherapy in 1987 (75% ini 1993) ard the 5 year local recurretnce rate for the irradiated was 6% of. 25% for the tnorn-irradiated. Primiary (uicoadjuivanit or pre-operative) cheimiothierapy for operable breast cancer lias conisistently benii shiowvn to achieve objective tumouir regressionis in 70% or more of patienits, with comiiplete clinical remiiissionis in arouinid 15-25%. In a recent Royal Marsdeni pilot study of 50 patienits inifuisionial ECF chemliothierapy (contilluous infusionial 5-FU with interitiitenit bolus epinibicin and cisplatini) achieved a 98% responise rate witli a comiiplete reimiissioni rate of 66%. This suggests that novel therapies may be more active tlhan conventional, and this lhypotlhesis is being tested in a miulticenitre randomiised trial (>300 patienits so far accrued), infusionial ECF is now being comlpared wvitl convenltionial AC (adriamycini, cyclophosphiamiiide 
